Arrowhead Pharmaceuticals Inc  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results for Kenneth D. Lewis
6.01
+0.26 (4.52%)
After Hours: 6.01 0.00 (0.00%)
Jul 27, 4:42PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.76 - 6.04
52 week 3.07 - 9.36
Open 5.76
Vol / Avg. 452,532.00/382,828.00
Mkt cap 366.74M
P/E     -
Div/yield     -
EPS -1.36
Shares 59.96M
Beta 2.36
Inst. own 35%
Aug 4, 2016
Q3 2016 Arrowhead Pharmaceuticals Inc Earnings Release - Tentative - 4:00PM EDT - Add to calendar
Jul 13, 2016
Arrowhead Pharmaceuticals Inc at Cantor Fitzgerald Healthcare Conference
Jun 10, 2016
Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference
May 10, 2016
Q2 2016 Arrowhead Pharmaceuticals Inc Earnings Call
May 10, 2016
Q2 2016 Arrowhead Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -47579.11% -24068.29%
Operating margin -48605.39% -25124.08%
EBITD margin - -24512.51%
Return on average assets -81.06% -58.36%
Return on average equity -99.75% -66.45%
Employees 104 -
CDP Score - -

Address

225 S Lake Ave Ste 1050
PASADENA, CA 91101-4820
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 for providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.

Officers and directors

Douglas B. Given M.D., Ph.D. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
David L. Lewis Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Peter Brian Leone Vice President-Strategy & Program Management
Age: 59
Bio & Compensation  - Reuters
Patrick O'Brien General Counsel
Age: 52
Bio & Compensation  - Reuters
Michael S. Perry Ph.D. Lead DirectorLead Independent Director
Age: 56
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D Independent Director
Age: 56
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 79
Bio & Compensation  - Reuters